This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NeoStem To Present At Multiple February Conferences

Stocks in this article: NBS

NEW YORK, Feb. 3, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), will present at multiple conferences in February.

BIO CEO 2014

  • Date and Time: Monday, February 10, 2014, 1:00 PM EST
  • Venue: The Waldorf Astoria, New York, New York
  • Session: Company Presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO of NeoStem

New York Stem Cell Summit 2014

  • Date: Tuesday, February 18, 2014
  • Venue: The Convene, Downtown, New York, New York
  • Session #1 Time: 11:00 AM EST
  • Session #1 Topic: Treating the Aging Patient With Stem Cells
  • Session #1 Speaker: Robin L. Smith, MD, MBA, Chairman and CEO of NeoStem
  • Session #2 Time: 3:36 PM EST
  • Session #2 Topic: Cutting Time to Market for Stem Cell Suppliers
  • Session #2 Speaker: Robert A. Preti, PhD, Chief Scientific Officer of NeoStem and PCT and President of PCT

GTC Cell & Gene Therapy Conference

  • Venue: Hyatt Regency Mission Bay, San Diego, California
  • Session #1 Date and Time: Thursday, February 20, 2014, 1:30 PM PST
  • Panel Topic: Emerging Technologies
  • Panel Moderator: Robert A. Preti, PhD, Chief Scientific Officer of NeoStem and PCT and President of PCT
  • Session #1 Topic: The Emerging Technology is Intrinsic Biotechnology
  • Session #1 Speaker: Jonathan Sackner-Bernstein, MD, FACC, Vice President, Clinical Development and New Technologies of NeoStem
  • Session #2 Date and Time: Friday, February 21, 2014, 1:40 PM PST
  • Panel Topic: Strategies for Commercialization
  • Panel Moderator: Robert A. Preti, PhD, Chief Scientific Officer of NeoStem and PCT and President of PCT
  • Session #2 Topic: Considerations for a Commercially Successful Cell Therapy Product
  • Session #2 Speaker: Sanjin Zvonic, PhD, Director, Technology & Business Development, PCT

About NeoStem, Inc.

NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs